These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30504370)

  • 1. Potent Antitumor T-Cell Memory Is Generated by Curative Viral Oncolytic Immunotherapy But Not Curative Chemotherapy.
    Gao Y; Bergman I
    Anticancer Res; 2018 Dec; 38(12):6621-6629. PubMed ID: 30504370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Memory T-Cells Become Functionally Mature from 30 to 100 days in a Mouse Model of Neoplasia.
    Gao Y; Barmada MA; Bergman I
    Anticancer Res; 2018 Jan; 38(1):147-157. PubMed ID: 29277767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.
    Gao Y; Whitaker-Dowling P; Griffin JA; Bergman I
    Cancer Gene Ther; 2012 Apr; 19(4):282-91. PubMed ID: 22240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
    Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
    J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
    Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG
    Mol Ther; 2008 Dec; 16(12):1910-8. PubMed ID: 18827807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
    Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
    Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic HSV as a vector in cancer immunotherapy.
    Li H; Zhang X
    Methods Mol Biol; 2010; 651():279-90. PubMed ID: 20686972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models.
    Veinalde R
    Methods Mol Biol; 2020; 2058():213-227. PubMed ID: 31486040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
    Breitbach CJ; Paterson JM; Lemay CG; Falls TJ; McGuire A; Parato KA; Stojdl DF; Daneshmand M; Speth K; Kirn D; McCart JA; Atkins H; Bell JC
    Mol Ther; 2007 Sep; 15(9):1686-93. PubMed ID: 17579581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
    Oh E; Choi IK; Hong J; Yun CO
    Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
    Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
    Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.